
|Videos|February 16, 2023
Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Advertisement
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience
2
Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis
3
Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control
4
Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year
5





















